Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3561-3580 of 3,900 trials

Esketamine for Schizophrenia Symptoms

We are studying whether esketamine can reduce depressive and negative symptoms in people with schizophrenia. The trial also looks at whether it causes any worsening of psychotic symptoms.

Negative and Depressive Symptoms in Schizophrenia and Schizoaffective Disorder≤3 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPsychiatry

Rheumatoid Arthritis: CLN-978 Treatment

We are testing a new treatment called CLN-978 for patients with rheumatoid arthritis who haven't found relief from existing medications. The goal is to see if it can help manage their symptoms better.

Rheumatoid Arthritis>2 yearsSafety phase (I)Rheumatology

Tozorakimab for Uncontrolled Asthma

We are studying whether different doses of tozorakimab can help adults with uncontrolled asthma reduce severe attacks. This trial compares the medication to a placebo to evaluate its effectiveness and safety.

Asthma1-2 yearsEfficacy phase (II)Investigational MedicinesPartially RemoteAllergologyPulmonology

High-Risk Thyroid Cancer: Neoadjuvant Pembrolizumab Study

We are studying the effects of pembrolizumab as a pre-surgery treatment for patients with high-risk thyroid cancers. The goal is to see if it improves outcomes and understand how the body responds to this therapy.

Thyroid CancerEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology

LY4057996: A Study in Diabetes

We are testing a new treatment in healthy participants and those with type 1 and type 2 diabetes. The goal is to learn more about its effects and safety in these different groups.

Healthy ParticipantsType 1 DiabetesType 2 DiabetesSafety phase (I)DiabetologyEndocrinology

Follicular Lymphoma: Golcadomide with Rituximab Study

We are comparing a new treatment combination to standard options for patients with relapsed or refractory follicular lymphoma. The study aims to see if this combination improves survival and quality of life.

Follicular LymphomaRelapsed/Refractory Follicular Lymphoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Testosterone Gel for Improving Recovery in Critically Ill Patients

We are studying whether daily testosterone gel can enhance physical performance and recovery in men and women during critical illness. This trial compares the gel to a placebo to see if it helps patients recover better after ICU admission.

Invasive Mechanical VentilationEfficacy phase (II)Standard MedicinesCost ReimbursementEndocrinologyInternal Medicine

Advanced Cancers: Testing IPH4502

We are investigating the safety and effects of a new drug, IPH4502, in people with advanced cancers. This study aims to understand how the drug works in humans for the first time.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Pasireotide: Injection Methods Study

We are investigating how well pasireotide is absorbed when given under the skin with a pen versus a syringe in healthy volunteers. This research may help improve how this medication is administered in the future.

Postprandial HypoglycemiaSafety phase (I)EndocrinologyInternal Medicine

Ovarian Cancer: PARP Inhibitor with Cisplatin and Heat Therapy

We are studying a new treatment approach for ovarian cancer that combines a PARP inhibitor with cisplatin and heat during surgery. This trial aims to see if this combination improves outcomes for patients.

Fallopian Tube CancerOvarian CancerExtraovarian Cancer>2 yearsSafety phase (I)Efficacy phase (II)Gynecology and ObstetricsOncology

New T Cell Therapy for Pediatric Blood Cancers

We are testing a modified T cell treatment for children with relapsed or hard-to-treat B-cell leukemia and lymphoma. The study aims to evaluate safety and effectiveness in helping these patients achieve remission.

Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia and Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncologyPediatrics

Advanced Solid Tumors: Testing IPN01195

We are studying a new medicine called IPN01195 to see how safe it is and what the best dose is for adults with advanced solid tumors. This trial aims to understand its effects on tumor activity and how it works in the body.

Advanced Solid Tumour3-6 monthsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementOncology

Staphylococcus Aureus Bacteremia: Comparing Antibiotic Durations

We are studying whether 7 days of antibiotic treatment is as effective as 14 days for patients with uncomplicated Staphylococcus aureus bacteremia. This may help reduce antibiotic use and hospital stays.

Staphylococcus aureus Bacteremia≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

HER2 Cancers: IAM1363 Treatment Study

We are testing IAM1363 in patients with HER2-positive cancers to see how safe it is and to find the right dosage. This study aims to gather important information for future treatments.

HER2 Gene Amplification1-2 yearsSafety phase (I)Oncology

Alzheimer's Disease: MK-2214 Study

We are testing a new medication, MK-2214, in people with early Alzheimer's disease to see if it may slow the progression of brain changes. The study will also evaluate the safety of this treatment compared to a placebo.

Alzheimer's Disease>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

AL Amyloidosis: Teclistamab Treatment Study

We are investigating whether teclistamab can improve blood health in patients with previously treated AL amyloidosis. This study will also look at the treatment's safety and its effects on quality of life.

Amyloid Light-Chain Amyloidosis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Blood Cancers: IDP-121 Treatment Study

We are testing a new medication, IDP-121, for patients with relapsed or refractory blood cancers like multiple myeloma and B-cell lymphoma. The goal is to find the best dose and see how well it helps improve patient outcomes.

Chronic Lymphocytic Leukemia (CLL)B-cell LymphomasMultiple Myeloma (MM)6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Neoadjuvant Chemo-Immunotherapy for Stage III PD-L1 Positive NSCLC

We are studying a combination of tislelizumab and chemotherapy for patients with stage III PD-L1 positive lung cancer. The aim is to see if this treatment improves surgery success and survival rates.

Stage III Non-Small Cell Lung CancerEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncologyPulmonology

Ravulizumab Dosing for PNH Patients

We are studying whether personalized dosing of ravulizumab is more effective than standard dosing for adults with PNH. This trial also looks at patient preferences and treatment costs.

Paroxysmal Nocturnal Hemoglobinuria1-2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyInternal Medicine

PF-07985631: Tolerance Study in Healthy Adults

We are investigating how different amounts of the study medicine PF-07985631 are tolerated by healthy adults. This study will help us understand its effects on the body.

IgA Nephropathy1-2 yearsSafety phase (I)Nephrology